Increlex (mecasermin [rDNA origin] injection)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
March 2016
ADVERSE REACTIONS
Immunogenicity
As with all therapeutic proteins, there is potential for immunogenicity. The...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Forteo